Compare AKBA & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | LYTS |
|---|---|---|
| Founded | 2007 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 700.9M |
| IPO Year | 2014 | N/A |
| Metric | AKBA | LYTS |
|---|---|---|
| Price | $1.48 | $18.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $6.25 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 5.0M | 196.9K |
| Earning Date | 11-10-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 1.09% |
| EPS Growth | N/A | ★ 2.57 |
| EPS | N/A | ★ 0.80 |
| Revenue | $225,071,000.00 | ★ $592,531,000.00 |
| Revenue This Year | $52.38 | $5.91 |
| Revenue Next Year | $22.45 | $8.03 |
| P/E Ratio | ★ N/A | $22.83 |
| Revenue Growth | ★ 32.49 | 22.35 |
| 52 Week Low | $1.46 | $13.77 |
| 52 Week High | $4.08 | $25.50 |
| Indicator | AKBA | LYTS |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 35.51 |
| Support Level | $1.52 | $17.79 |
| Resistance Level | $1.63 | $18.60 |
| Average True Range (ATR) | 0.10 | 0.56 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 1.15 | 42.00 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.